Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1315  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (245 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed2049    
    Printed78    
    Emailed1    
    PDF Downloaded93    
    Comments [Add]    

Recommend this journal

 


 
CORRESPONDENCE
Year : 2009  |  Volume : 57  |  Issue : 6  |  Page : 837

Mitroxantrone in multiple sclerosis


University College of Medical Sciences, New Delhi, India

Date of Acceptance15-Dec-2009
Date of Web Publication30-Jan-2010

Correspondence Address:
Sourabh Aggarwal
University College of Medical Sciences, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.59504

Rights and Permissions



How to cite this article:
Aggarwal S. Mitroxantrone in multiple sclerosis. Neurol India 2009;57:837

How to cite this URL:
Aggarwal S. Mitroxantrone in multiple sclerosis. Neurol India [serial online] 2009 [cited 2019 Jul 16];57:837. Available from: http://www.neurologyindia.com/text.asp?2009/57/6/837/59504


Sir,

I read the article 'Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting' [1] with interest. I applaud the authors for conducting such a study in Indian setup. The beneficence of low cost involved in the treatment of multiple sclerosis with mitroxantrone need to be evaluated against the cost involved in dealing with the significant morbidity caused due to potential side effects of the drug therapy. The ethical justification of initiating such therapy in relatively milder form of disease is a matter of serious discussion and will be debated upon for a long time to come. Nonetheless, the authors have done a commendable job in view of patients seriously impaired by multiple sclerosis who cannot afford first line treatment, though large scale study will be needed to complement the results of this study.

 
  References Top

1.Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting. Neurol India 2009;57:418-23.  Back to cited text no. 1  [PUBMED]  Medknow Journal  




 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow